Structure Therapeutics (NASDAQ:GPCR) Reaches New 12-Month Low – Should You Sell?

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR) reached a new 52-week low during trading on Tuesday . The company traded as low as $26.03 and last traded at $26.63, with a volume of 791474 shares trading hands. The stock had previously closed at $29.04.

Analyst Ratings Changes

Several research analysts have recently weighed in on GPCR shares. Cantor Fitzgerald restated an “overweight” rating and set a $65.00 target price on shares of Structure Therapeutics in a report on Monday, September 23rd. HC Wainwright reissued a “buy” rating and set a $80.00 price objective on shares of Structure Therapeutics in a research note on Thursday, December 19th. Morgan Stanley assumed coverage on Structure Therapeutics in a research note on Monday, September 23rd. They issued an “overweight” rating and a $118.00 target price for the company. Finally, JMP Securities reissued a “market outperform” rating and set a $91.00 price target on shares of Structure Therapeutics in a research report on Wednesday, December 18th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $86.50.

Structure Therapeutics Price Performance

The company has a market cap of $1.52 billion, a price-to-earnings ratio of -35.99 and a beta of -3.41. The firm has a 50 day simple moving average of $34.13 and a 200-day simple moving average of $37.61.

Institutional Trading of Structure Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Bank of Montreal Can purchased a new position in Structure Therapeutics during the second quarter worth about $1,064,000. Vestal Point Capital LP boosted its position in shares of Structure Therapeutics by 105.4% during the 3rd quarter. Vestal Point Capital LP now owns 1,150,000 shares of the company’s stock worth $50,474,000 after purchasing an additional 590,000 shares during the period. Lighthouse Investment Partners LLC acquired a new stake in Structure Therapeutics in the 2nd quarter valued at approximately $1,178,000. abrdn plc raised its position in Structure Therapeutics by 132.7% in the third quarter. abrdn plc now owns 217,083 shares of the company’s stock valued at $9,528,000 after purchasing an additional 123,789 shares during the period. Finally, Pier Capital LLC lifted its stake in Structure Therapeutics by 32.7% during the third quarter. Pier Capital LLC now owns 134,291 shares of the company’s stock worth $5,894,000 after purchasing an additional 33,087 shares in the last quarter. 91.78% of the stock is owned by institutional investors and hedge funds.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.